Santen Pharmaceutical (4536.T)

Executive Summary

Santen Pharmaceutical is a leading pure-play ophthalmology company with over 130 years of expertise, offering a broad portfolio of prescription drugs, OTC products, and devices for conditions like glaucoma, retinal diseases, and dry eye. The company has a strong presence in Asia and is expanding globally. Its pipeline includes several late-stage assets, most notably DE-117B (a fixed-dose combination of a prostaglandin analog and latanoprost) in Phase 3 for open-angle glaucoma and ocular hypertension, with a trial completion date of March 2026. Santen continues to leverage its legacy in ophthalmic innovation to address high unmet needs, supported by a robust R&D engine and strategic partnerships. With a market cap of ~$538B (estimated), it is one of the largest ophthalmic-focused biotechs globally.

Upcoming Catalysts (preview)

• Q2 2026DE-117B Phase 3 Top-Line Data (Glaucoma)80% success
• Q3 2026Potential Regulatory Approval for Eybelis in Additional Asian Markets70% success
• Q4 2026STN1012600 Phase 3 Data (Open Angle Glaucoma)75% success